Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness

Erwin W. Gelfand, Zhi Hua Cui, Katsuyuki Takeda, Arihiko Kanehiro, Anthony Joetham

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Antihistamines have been evaluated for usefulness in the treatment of asthma for more than 50 years. Interest was limited until the introduction of newer compounds that were free of much of the dose-limiting sedation associated with the earlier drugs. Objective: In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the efficacy of an H1 receptor antagonist to prevent allergic inflammation and altered airway function was evaluated. Methods: Mice were sensitized and challenged to an allergen, ovalbumin, which elicited marked airway and tissue eosinophilia and airway hyperresponsiveness. Fexofenadine was administered before challenge, and airway responsiveness to inhaled methacholine, airway and tissue eosinophilia, bronchoalveolar lavage fluid cytokine levels, and serum IgE levels were assayed. In a second group of experiments, sensitized and challenged mice were treated or not treated with fexofenadine before challenge. T cells were isolated from the lungs and adoptively transferred into naive recipients before exposure to limited airway allergen challenge, and lung function and inflammation were evaluated. Results: Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. These changes were accompanied by decreases in bronchoalveolar lavage and tissue eosinophilia, lymphocyte numbers, and TH2 cytokine production. Conclusion: The results demonstrate the efficacy of an H1 receptor antagonist in preventing allergen-induced alterations in pulmonary inflammation and airway function. The data support the evaluation of drugs such as fexofenadine in the treatment of allergic asthma.

Original languageEnglish
Pages (from-to)85-95
Number of pages11
JournalJournal of Allergy and Clinical Immunology
Volume110
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

fexofenadine
Allergens
Eosinophilia
Inflammation
T-Lymphocytes
Histamine H1 Receptors
Pneumonia
Asthma
Cytokines
Drug Evaluation
Adoptive Transfer
Methacholine Chloride
Histamine Antagonists
Ovalbumin
Bronchoalveolar Lavage Fluid
Lymphocyte Count
Bronchoalveolar Lavage
Immunoglobulin E
Therapeutics
Lung

Keywords

  • Airway hyperresponsiveness
  • Allergen
  • Fexofenadine
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. / Gelfand, Erwin W.; Cui, Zhi Hua; Takeda, Katsuyuki; Kanehiro, Arihiko; Joetham, Anthony.

In: Journal of Allergy and Clinical Immunology, Vol. 110, No. 1, 2002, p. 85-95.

Research output: Contribution to journalArticle

Gelfand, Erwin W. ; Cui, Zhi Hua ; Takeda, Katsuyuki ; Kanehiro, Arihiko ; Joetham, Anthony. / Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. In: Journal of Allergy and Clinical Immunology. 2002 ; Vol. 110, No. 1. pp. 85-95.
@article{a6614b2bac554134af525735c85036b1,
title = "Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness",
abstract = "Background: Antihistamines have been evaluated for usefulness in the treatment of asthma for more than 50 years. Interest was limited until the introduction of newer compounds that were free of much of the dose-limiting sedation associated with the earlier drugs. Objective: In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the efficacy of an H1 receptor antagonist to prevent allergic inflammation and altered airway function was evaluated. Methods: Mice were sensitized and challenged to an allergen, ovalbumin, which elicited marked airway and tissue eosinophilia and airway hyperresponsiveness. Fexofenadine was administered before challenge, and airway responsiveness to inhaled methacholine, airway and tissue eosinophilia, bronchoalveolar lavage fluid cytokine levels, and serum IgE levels were assayed. In a second group of experiments, sensitized and challenged mice were treated or not treated with fexofenadine before challenge. T cells were isolated from the lungs and adoptively transferred into naive recipients before exposure to limited airway allergen challenge, and lung function and inflammation were evaluated. Results: Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. These changes were accompanied by decreases in bronchoalveolar lavage and tissue eosinophilia, lymphocyte numbers, and TH2 cytokine production. Conclusion: The results demonstrate the efficacy of an H1 receptor antagonist in preventing allergen-induced alterations in pulmonary inflammation and airway function. The data support the evaluation of drugs such as fexofenadine in the treatment of allergic asthma.",
keywords = "Airway hyperresponsiveness, Allergen, Fexofenadine, Inflammation",
author = "Gelfand, {Erwin W.} and Cui, {Zhi Hua} and Katsuyuki Takeda and Arihiko Kanehiro and Anthony Joetham",
year = "2002",
doi = "10.1067/mai.2002.124770a",
language = "English",
volume = "110",
pages = "85--95",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness

AU - Gelfand, Erwin W.

AU - Cui, Zhi Hua

AU - Takeda, Katsuyuki

AU - Kanehiro, Arihiko

AU - Joetham, Anthony

PY - 2002

Y1 - 2002

N2 - Background: Antihistamines have been evaluated for usefulness in the treatment of asthma for more than 50 years. Interest was limited until the introduction of newer compounds that were free of much of the dose-limiting sedation associated with the earlier drugs. Objective: In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the efficacy of an H1 receptor antagonist to prevent allergic inflammation and altered airway function was evaluated. Methods: Mice were sensitized and challenged to an allergen, ovalbumin, which elicited marked airway and tissue eosinophilia and airway hyperresponsiveness. Fexofenadine was administered before challenge, and airway responsiveness to inhaled methacholine, airway and tissue eosinophilia, bronchoalveolar lavage fluid cytokine levels, and serum IgE levels were assayed. In a second group of experiments, sensitized and challenged mice were treated or not treated with fexofenadine before challenge. T cells were isolated from the lungs and adoptively transferred into naive recipients before exposure to limited airway allergen challenge, and lung function and inflammation were evaluated. Results: Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. These changes were accompanied by decreases in bronchoalveolar lavage and tissue eosinophilia, lymphocyte numbers, and TH2 cytokine production. Conclusion: The results demonstrate the efficacy of an H1 receptor antagonist in preventing allergen-induced alterations in pulmonary inflammation and airway function. The data support the evaluation of drugs such as fexofenadine in the treatment of allergic asthma.

AB - Background: Antihistamines have been evaluated for usefulness in the treatment of asthma for more than 50 years. Interest was limited until the introduction of newer compounds that were free of much of the dose-limiting sedation associated with the earlier drugs. Objective: In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the efficacy of an H1 receptor antagonist to prevent allergic inflammation and altered airway function was evaluated. Methods: Mice were sensitized and challenged to an allergen, ovalbumin, which elicited marked airway and tissue eosinophilia and airway hyperresponsiveness. Fexofenadine was administered before challenge, and airway responsiveness to inhaled methacholine, airway and tissue eosinophilia, bronchoalveolar lavage fluid cytokine levels, and serum IgE levels were assayed. In a second group of experiments, sensitized and challenged mice were treated or not treated with fexofenadine before challenge. T cells were isolated from the lungs and adoptively transferred into naive recipients before exposure to limited airway allergen challenge, and lung function and inflammation were evaluated. Results: Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. These changes were accompanied by decreases in bronchoalveolar lavage and tissue eosinophilia, lymphocyte numbers, and TH2 cytokine production. Conclusion: The results demonstrate the efficacy of an H1 receptor antagonist in preventing allergen-induced alterations in pulmonary inflammation and airway function. The data support the evaluation of drugs such as fexofenadine in the treatment of allergic asthma.

KW - Airway hyperresponsiveness

KW - Allergen

KW - Fexofenadine

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0036965595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036965595&partnerID=8YFLogxK

U2 - 10.1067/mai.2002.124770a

DO - 10.1067/mai.2002.124770a

M3 - Article

VL - 110

SP - 85

EP - 95

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -